Zavicefta 2g/0.5g powder for concentrate for solution for infusion

  • Name:

    Zavicefta 2g/0.5g powder for concentrate for solution for infusion

  • Company:
    info
  • Active Ingredients:

    Ceftazidime Pentahydrate, Avibactam sodium

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 15/04/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 12/4/2019
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

Click on this link to Download PDF directly

Pfizer Healthcare Ireland

Pfizer Healthcare Ireland

Company Products

Medicine NameActive Ingredients
Medicine Name Trazimera - 150mg & 420mg powder for solution for infusion Active Ingredients Trastuzumab
Medicine Name Trosyl 283mg/ml Nail Solution Active Ingredients Tioconazole
Medicine Name TRUMENBA Active Ingredients Meningococcal group B vaccine (recombinant, adsorbed)
Medicine Name Tygacil 50mg powder for solution for infusion Active Ingredients Tigecycline
Medicine Name VFEND 200 mg powder and solvent for solution for infusion Active Ingredients Voriconazole
Medicine Name VFEND 200 mg powder for solution for infusion Active Ingredients Voriconazole
Medicine Name VFEND 40mg/ml powder for oral suspension Active Ingredients Voriconazole
Medicine Name VFend 50mg and 200mg film-coated tablets Active Ingredients Voriconazole
Medicine Name Viagra 25MG, 50MG, 100MG Active Ingredients sildenafil citrate
Medicine Name Vibramycin Capsules 100mg Active Ingredients Doxycycline hyclate
Medicine Name Vinblastine Sulfate 1 mg/ml Solution for Injection or Infusion Active Ingredients Vinblastine sulfate
Medicine Name Vincristine Sulphate 1 mg/ml Solution for Injection or Infusion Active Ingredients Vincristine sulphate
Medicine Name Vizimpro 15, 30 & 45 mg film-coated tablets Active Ingredients dacomitinib monohydrate
Medicine Name Xalacom eye drops, solution Active Ingredients Latanoprost, Timolol Maleate
Medicine Name Xalatan 50 micrograms/ml eye drops solution Active Ingredients Latanoprost
Medicine Name Xalkori 200mg and 250 mg hard capsules Active Ingredients Crizotinib
Medicine Name Xanax 1 mg Tablets Active Ingredients Alprazolam
Medicine Name Xanax 500 microgram Tablets Active Ingredients Alprazolam
Medicine Name Xanax Tablets 250 micrograms Active Ingredients Alprazolam
Medicine Name Xeljanz 10mg film coated tablets Active Ingredients Tofacitinib citrate
Medicine Name Xeljanz 5mg film coated tablets Active Ingredients Tofacitinib citrate
Medicine Name Zavedos 5mg Powder for Solution for Injection Active Ingredients Idarubicin Hydrochloride
Medicine Name Zavicefta 2g/0.5g powder for concentrate for solution for infusion Active Ingredients Ceftazidime Pentahydrate, Avibactam sodium
Medicine Name Zinforo 600 mg powder for concentrate for solution for infusion Active Ingredients Ceftaroline Fosamil
Medicine Name ZITHROMAX CAPSULES 250MG Active Ingredients Azithromycin dihydrate
201 - 225 of 231 items.Total: 10 pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 15 April 2019 PIL

Reasons for updating

  • Change to section 6 - date of revision

Updated on 12 April 2019 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 31 October 2018 PIL

Reasons for updating

  • Change to section 6 - date of revision

Updated on 31 October 2018 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

Section 10: DATE OF REVISION OF THE TEXT has been updated – (10/2018)

Updated on 25 July 2018 PIL

Reasons for updating

  • Change to section 2 - excipient warnings
  • Improved presentation of PIL

Updated on 25 July 2018 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Sections 4.2 (Posology and method of administration) and 4.8 (Undesirable effects) updated following completion of the paediatric study C3591004.

Section 4.4 sodium statement updated to align with the Annex to the EU Commission guideline on ‘Excipients in the labelling and package leaflet of medicinal products for human use’.

Updated on 6 February 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 6 February 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:
Section 7 - MA Holder address "Operations Services Group" corrected to "Operations Support Group".

Updated on 5 February 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 5 February 2018 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 8 January 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 8 January 2018 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided